Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways

24:23
 
Share
 

Manage episode 428381804 series 3256997
Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

In this podcast episode, Julio C. Chavez, MD, MS, and Alan Skarbnik, MD, discuss the emerging role of CELMoDs in NHL care, including:

  • Rationale for targeting CELMoDs in NHL
  • Mechanism of action of CELMoDs
  • Key studies and available efficacy and safety data with investigational CELMoDs in NHL
  • Key ongoing clinical trials of CELMoDs in NHL
  • Strategies to boost NHL clinical trial diversity among underserved communities

Presenters:

Julio C. Chavez, MD, MS
Associate Member
Department of Malignant Hematology
ICE-T Clinical Research Medical Director for Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Associate Professor
University of South Florida
Tampa, Florida

Alan Skarbnik, MD
Director, Lymphoma and CLL Program
Director, Immune Effector Cell Therapeutics Program
Novant Health Cancer Institute
Charlotte, North Carolina

Content based on an online CME program supported by educational grants from Bristol-Myers Squibb.

Link to full program:
https://bit.ly/45YXoZI

  continue reading

191 episodes

Artwork
iconShare
 
Manage episode 428381804 series 3256997
Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

In this podcast episode, Julio C. Chavez, MD, MS, and Alan Skarbnik, MD, discuss the emerging role of CELMoDs in NHL care, including:

  • Rationale for targeting CELMoDs in NHL
  • Mechanism of action of CELMoDs
  • Key studies and available efficacy and safety data with investigational CELMoDs in NHL
  • Key ongoing clinical trials of CELMoDs in NHL
  • Strategies to boost NHL clinical trial diversity among underserved communities

Presenters:

Julio C. Chavez, MD, MS
Associate Member
Department of Malignant Hematology
ICE-T Clinical Research Medical Director for Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Associate Professor
University of South Florida
Tampa, Florida

Alan Skarbnik, MD
Director, Lymphoma and CLL Program
Director, Immune Effector Cell Therapeutics Program
Novant Health Cancer Institute
Charlotte, North Carolina

Content based on an online CME program supported by educational grants from Bristol-Myers Squibb.

Link to full program:
https://bit.ly/45YXoZI

  continue reading

191 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play